cullinanoncology.com (CGEM) - יתרות מזומנים למניה אחת

סמל תאגידי ולוגו של Cullinan Corp (CGEM)

Portfolio diversification toward autoimmune pathologies reduces risks, as confirmed by the cash per share history on the GURU.Markets intraday chart, where the value of 4.46 serves as the current metric. Meanwhile, Cullinan Therapeutics (CGEM) remains a loss-making biotech with no revenue, consuming capital for research, although confidence in the brand as an innovator is currently growing rapidly.

cullinanoncology.com (CGEM) - מזומנים למניה אחת מ-04.07.2022 עד 20.11.2026

פילוחי מדדים מקיפים ואנליטיקה עבור Cullinan Corp (CGEM)

- פרטי פוזיציית מזומנים ותזרימי מזומנים:
ניתוח מקיף של החברה:Cullinan Therapeutics Inc - CGEM
סחורת הדגל של Cullinan Therapeutics Inc

For the biotechnology company Cullinan Therapeutics (CGEM), whose operations are limited to clinical trials without generating its own revenue, liquidity control is critical prior to receiving FDA approvals. This metric is calculated as the ratio of net cash balance to the number of shares outstanding, allowing investors to assess the financial runway and the risk of a cash crunch by analyzing the cash per share chart.